NBY NovaBay Pharmaceuticals Inc.

0.58
0  0%
Previous Close 0.58
Open 0.58
Price To Book 5.85
Market Cap 16,317,002
Shares 27,901,850
Volume 149,846
Short Ratio 1.13
Av. Daily Volume 662,599
Stock charts supplied by TradingView

NewsSee all news

  1. NovaBay Pharmaceuticals Launches NovaWipes Eyelid Wipes on Amazon.com

    Dry wipes are specifically designed for applying Avenova® to treat dry eye and blepharitis NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the launch of NovaWipes, a dry, soft, hypoallergenic and absorbable wipe

  2. NovaBay Pharmaceuticals Launches NovaSight™ Daily Vitamin for Ocular Health on Amazon.com

    NovaSight complements Avenova® Direct for comprehensive internal and external eye health NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the launch of NovaSight™, a proprietary daily vitamin and mineral supplement

  3. NovaBay Pharmaceuticals Reports 2019 Third Quarter Financial Results

    Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial

  4. NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures

    Prescription-strength CelleRx to gently clean skin and ease post-procedure discomfort is now available without a prescription at www.CelleRx.com NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the availability of

  5. NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial results after

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Data released August 2014. Endpoints not met
Auriclosene (NVC-422)
Viral conjunctivitis
Failed to meet endpoint Nov 2013. Plans to reinitiate trial in 2014
Auriclosene (NVC-422)
Impetigo skin infection study

Latest News

  1. NovaBay Pharmaceuticals Launches NovaWipes Eyelid Wipes on Amazon.com

    Dry wipes are specifically designed for applying Avenova® to treat dry eye and blepharitis NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the launch of NovaWipes, a dry, soft, hypoallergenic and absorbable wipe

  2. NovaBay Pharmaceuticals Launches NovaSight™ Daily Vitamin for Ocular Health on Amazon.com

    NovaSight complements Avenova® Direct for comprehensive internal and external eye health NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the launch of NovaSight™, a proprietary daily vitamin and mineral supplement

  3. NovaBay Pharmaceuticals Reports 2019 Third Quarter Financial Results

    Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial

  4. NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures

    Prescription-strength CelleRx to gently clean skin and ease post-procedure discomfort is now available without a prescription at www.CelleRx.com NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the availability of

  5. NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial results after

  6. NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies

    Once-daily system complements Avenova and leverages salesforce calls on eyecare specialists NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic

  7. NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in Australia

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it has received approval for the distribution of Avenova from

  8. NovaBay Pharmaceuticals Names Finance Executive Jeff Zheng to its Board of Directors

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that Yenyou (Jeff) Zheng, Ph.D. has joined the Company's board as

  9. NovaBay Pharmaceuticals to Present at Two Investment Conferences in September

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that management will present at two upcoming investment